Search

Displaying results 271 - 280 of 4188 in total
  1. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. … It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

  2. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    Approved

    Recently there has been pressure to stop prescribing docusate as it has been identified as an ineffective medicine[A176972,A176987,L5912]. … Docusate acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass [L1801]. Docusate can be orally or rectally administered.

  3. Drug

    Methylnaltrexone

    go.drugbank.com/drugs/DB06800
    ApprovedInvestigational

    Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.

  4. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. … Gene therapy with autologous hematopoietic stem cells was introduced and investigated as a possible treatment for patients with adrenoleukodystrophy.

    Categories: Cellular and Gene Therapy
  5. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    A barbituric acid derivative that acts as a nonselective central nervous system depressant.

  6. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  7. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    [A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation.

  8. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. … The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

  9. Indication

    HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC)

    go.drugbank.com/conditions/DBCOND0159058
    Drugs: Talazoparib
    Synonyms: HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC)
  10. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors [A31846]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].